|
Market Closed -
NSE India S.E.
04:35:07 20/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 2,648.00 INR | +1.51% |
|
-0.44% | +30.11% |
| 09/11 | Acucort signs exclusive agreement for Zeqmelit in Canada - launch expected in 2028 | FW |
| 06/11 | Glenmark Pharmaceuticals Limited, Q2 2027 Earnings Call, Nov 06, 2026 |
| Market Cap | 75TCr 807.04Cr 735.05Cr 677.31Cr 616.1Cr 1.16TCr 1.21TCr 8.24TCr 3.28TCr 41TCr 3.03TCr 2.96TCr 1,28100Cr | P/E 2027 * |
33.4x | P/E 2028 * | 27.2x |
|---|---|---|---|---|---|
| Enterprise Value | 74TCr 793.81Cr 723Cr 666.2Cr 606Cr 1.14TCr 1.19TCr 8.11TCr 3.22TCr 40TCr 2.98TCr 2.92TCr 1,26000Cr | EV / Sales 2027 * |
4.34x | EV / Sales 2028 * | 3.86x |
| Free-Float |
51.04% | Yield 2027 * |
0.16% | Yield 2028 * | 0.15% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| GLENMARK | Delayed | |
| GLENMARK | Delayed |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | +1.51% | ||
| 1 week | -0.44% | ||
| Current month | +15.20% | ||
| 1 month | +19.81% | ||
| 3 months | +17.87% | ||
| 6 months | +10.06% | ||
| Current year | +30.11% |
| 1 week | 2,600.2 | 2,691.5 | |
| 1 month | 2,101.6 | 2,714 | |
| Current year | 1,842 | 2,714 | |
| 1 year | 1,825.1 | 2,714 | |
| 3 years | 761 | 2,714 | |
| 5 years | 348.5 | 2,714 | |
| 10 years | 161.65 | 2,714 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 01/01/2000 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 27/05/2025 |
Indrajit Bose
PSD | President | - | 15/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 57 | 12/05/2011 | |
| Director/Board Member | 86 | 14/08/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.51% | -0.44% | +43.85% | +241.26% | 788.24Cr | ||
| -0.30% | -5.62% | +28.35% | +127.66% | 1,20400Cr | ||
| +1.25% | -4.60% | +33.56% | +80.57% | 64TCr | ||
| +0.94% | -2.80% | +22.88% | +106.94% | 50TCr | ||
| -0.60% | -2.39% | +27.92% | +67.00% | 38TCr | ||
| +0.69% | -9.00% | +40.68% | +31.42% | 33TCr | ||
| +0.41% | -4.81% | +24.99% | +51.91% | 28TCr | ||
| +0.81% | -3.72% | -1.35% | +30.72% | 27TCr | ||
| -0.15% | -6.73% | +27.23% | +64.15% | 24TCr | ||
| -0.06% | -0.91% | +29.95% | +120.58% | 21TCr | ||
| Average | +0.80% | -4.15% | +27.81% | +92.22% | 41TCr | |
| Weighted average by Cap. | +0.62% | -4.70% | +27.28% | +88.61% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 17TCr 182.92Cr 166.61Cr 153.52Cr 139.65Cr 261.98Cr 275.34Cr 1.87TCr 742.61Cr 9.25TCr 686.33Cr 671.86Cr 29TCr | 19TCr 203.09Cr 184.98Cr 170.45Cr 155.04Cr 290.87Cr 305.7Cr 2.07TCr 824.5Cr 10TCr 762.01Cr 745.95Cr 32TCr |
| Net income | 2.2TCr 24Cr 22Cr 20Cr 18Cr 34Cr 36Cr 242.25Cr 96Cr 1.2TCr 89Cr 87Cr 3.76TCr | 2.74TCr 30Cr 27Cr 25Cr 23Cr 42Cr 44Cr 301.73Cr 119.92Cr 1.49TCr 110.83Cr 108.5Cr 4.69TCr |
| Net Debt | -1.23TCr -13Cr -12Cr -11Cr -10Cr -19Cr -20Cr -135.15Cr -54Cr -669.24Cr -50Cr -49Cr -2.1TCr | -2.17TCr -23Cr -21Cr -20Cr -18Cr -34Cr -35Cr -239.53Cr -95Cr -1.19TCr -88Cr -86Cr -3.72TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | ₹2,648.00 | +1.51% | 5,40,171 |
| 19/26/19 | ₹2,608.50 | -1.42% | 3,92,816 |
| 18/26/18 | ₹2,646.10 | +1.16% | 10,88,198 |
| 17/26/17 | ₹2,615.80 | -0.65% | 2,92,746 |
| 16/26/16 | ₹2,632.90 | -0.27% | 3,51,491 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
















